Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2017.00747 http://scihub22266oqcxt.onion/10.3389/fimmu.2017.00747 C5491903!5491903 !28713374     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28713374 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Front+Immunol 2017 ; 8 (ä): 747 Nephropedia Template TP {{tp|p=28713374 |t=2017. The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation |pdf=|usr=}}{{28713374 }} gab.com Text The Selective Phosphoinoside-3-Kinase p110 Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=28713374 #FOAvip The class I phosphoinoside-3-kinases (PI3Ks) are important enzymes that relay signals from cell surface receptors to downstream mediators driving cellular functions. Elevated PI3K signaling is found in B cell malignancies and lymphocytes of patients with autoimmune disease. The p110? catalytic isoform of PI3K is a rational target since it is critical for B lymphocyte development, survival, activation, and differentiation. In addition, activating mutations in PIK3CD encoding p110? cause a human immunodeficiency known as activated PI3K delta syndrome. Currently, idelalisib is the only selective p110? inhibitor that has been FDA approved to treat certain B cell malignancies. p110? inhibitors can suppress autoantibody production in mouse models, but limited clinical trials in human autoimmunity have been performed with PI3K inhibitors to date. Thus, there is a need for additional tools to understand the effect of pharmacological inhibition of PI3K isoforms in lymphocytes. In this study, we tested the effects of a potent and selective p110? inhibitor, IPI-3063, in assays of B cell function. We found that IPI-3063 potently reduced mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1, almost to the same degree as a pan-PI3K inhibitor. Similarly, IPI-3063 potently inhibited human B cell proliferation in vitro. The p110? isoform has partially overlapping roles with p110? in B cell development, but little is known about its role in B cell function. We found that the p110? inhibitor AS-252424 had no significant impact on B cell responses. A novel dual p110?/? inhibitor, IPI-443, had comparable effects to p110? inhibition alone. These findings show that p110? is the dominant isoform mediating B cell responses and establish that IPI-3063 is a highly potent molecule useful for studying p110? function in immune cells. Twit Text FOAVip The Selective Phosphoinoside-3-Kinase p110 Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=28713374 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28713374 #FOAvip English Wikipedia <ref>{{Cite pmid|28713374 }}</ref> The Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation #MMPMID28713374 Chiu H ; Mallya S ; Nguyen P ; Mai A ; Jackson LV ; Winkler DG ; DiNitto JP ; Brophy EE ; McGovern K ; Kutok JL ; Fruman DA Front Immunol 2017[]; 8 (ä): 747 PMID28713374 show ga The class I phosphoinoside-3-kinases (PI3Ks) are important enzymes that relay signals from cell surface receptors to downstream mediators driving cellular functions. Elevated PI3K signaling is found in B cell malignancies and lymphocytes of patients with autoimmune disease. The p110? catalytic isoform of PI3K is a rational target since it is critical for B lymphocyte development, survival, activation, and differentiation. In addition, activating mutations in PIK3CD encoding p110? cause a human immunodeficiency known as activated PI3K delta syndrome. Currently, idelalisib is the only selective p110? inhibitor that has been FDA approved to treat certain B cell malignancies. p110? inhibitors can suppress autoantibody production in mouse models, but limited clinical trials in human autoimmunity have been performed with PI3K inhibitors to date. Thus, there is a need for additional tools to understand the effect of pharmacological inhibition of PI3K isoforms in lymphocytes. In this study, we tested the effects of a potent and selective p110? inhibitor, IPI-3063, in assays of B cell function. We found that IPI-3063 potently reduced mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1, almost to the same degree as a pan-PI3K inhibitor. Similarly, IPI-3063 potently inhibited human B cell proliferation in vitro. The p110? isoform has partially overlapping roles with p110? in B cell development, but little is known about its role in B cell function. We found that the p110? inhibitor AS-252424 had no significant impact on B cell responses. A novel dual p110?/? inhibitor, IPI-443, had comparable effects to p110? inhibition alone. These findings show that p110? is the dominant isoform mediating B cell responses and establish that IPI-3063 is a highly potent molecule useful for studying p110? function in immune cells. äThe Selective Phosphoinoside-3-Kinase p110? Inhibitor IPI-3063 Potentl(epmc).pdf DeepDyve Pubget Overpricing